If you have been reading about melanocortin receptor and want a single page that covers the useful parts, this is it: definitions, context, how it is studied, and the questions that come up repeatedly.
Last reviewed on 2026-03-12. Where a claim depends on a specific study, the study is described rather than over-claimed.
Bremelanotide is a moderately large peptide with a molecular mass near 1025 daltons. In lyophilised form it appears as a white to off-white powder and is freely soluble in water and other polar solvents. The intact lactam ring is essential for receptor affinity, while linearised fragments bind far more weakly. Solutions are sensitive to extremes of pH and to prolonged exposure to light and heat, so handling typically involves buffered conditions and cold storage. Its short plasma half-life reflects rapid distribution and clearance rather than chemical breakdown inside the vial.
Development of the peptide passed through several delivery formats, including an intranasal version tested in early trials and an injectable version that entered later clinical study. Regulatory approval for a subcutaneous product in the United States was granted in 2019 after review of controlled trials in premenopausal women. Outside the clinic, the compound circulates in research and non-pharmaceutical markets under its code name, where identity and purity vary considerably between suppliers. Synonyms appearing across technical literature include bremelanotide, PT-141, and Palatin 141.
PT-141 is the research designation for bremelanotide, a synthetic cyclic heptapeptide developed as a melanocortin receptor agonist. The peptide contains seven amino acids with an internal lactam bridge that constrains the backbone into a stable ring. Cyclisation of this kind improves resistance to enzymatic degradation relative to linear analogues. The compound was first explored for effects on melanin production, because several melanocortin receptors influence pigmentation. Its later association with sexual desire emerged from observations made during that early work, and the molecule became the subject of a separate development programme.
How receptor activation translates into a change in desire is not established in detail. Proposed steps include modulation of dopaminergic signalling in reward circuits and downstream effects on autonomic tone. Human data consist mainly of clinical trials measuring self-reported outcomes rather than direct measurements of brain activity or transmitter release. The transient rise in blood pressure sometimes observed after administration is likewise reported consistently but explained only partly by known melanocortin pathways.
Melanocortin receptors form a family of five G-protein-coupled proteins, labelled MC1R through MC5R, that respond to peptides derived from pro-opiomelanocortin. Alpha-melanocyte-stimulating hormone and adrenocorticotropic hormone are the best-known endogenous ligands. The receptors are distributed differently across tissues, so a single agonist can produce effects in the brain, skin, adrenal gland and vasculature. This distribution explains why one peptide can influence both pigmentation and motivated behaviour.
Bremelanotide is a cyclic heptapeptide that binds several melanocortin receptors rather than one. In vitro assays report agonist activity at MC1R, MC3R, MC4R and MC5R, with MC4R generally treated as the subtype most relevant to sexual effects. MC4R is expressed in hypothalamic nuclei involved in appetite, energy balance and motivated behaviour, which provides a plausible route for central action. Selective MC4R agonists studied in animals produce comparable behavioural changes, supporting that interpretation.
| Property | Value | Notes |
|---|---|---|
| Chemical class | Cyclic heptapeptide | Synthetic melanocortin analogue |
| Molecular formula | C50H68N14O10 | Corresponds to a mass near 1025 daltons |
| Appearance | White to off-white powder | Lyophilised solid before reconstitution |
| Solubility | Soluble in water and polar solvents | Poor solubility in nonpolar media |
| Common synonyms | Bremelanotide, PT-141 | Code name and international name used interchangeably |
Bremelanotide acts as a non-selective agonist at melanocortin receptors, with reported activity at MC1R, MC3R, MC4R and MC5R. The proposed basis for its central effects is activation of MC4R populations in the hypothalamus, a region associated with appetite and reproductive signalling. Because the peptide carries a net positive charge and polar side chains, it does not cross biological membranes freely, which is one reason oral administration is not the standard route. Effects generally appear within an hour of parenteral administration and are described as centrally mediated rather than peripheral.
Bremelanotide, developed under the code PT-141, is a synthetic cyclic heptapeptide analogue of alpha-melanocyte-stimulating hormone. Its structure is Ac-Nle-cyclo[Asp-His-D-Phe-Arg-Trp-Lys]-OH, with a lactam bridge joining the aspartate and lysine side chains. The molecule has the formula C50H68N14O10 and a monoisotopic mass near 1025 daltons. It is commonly prepared as the acetate salt and appears as a white to off-white lyophilised powder in solid form. The free acid is the pharmacologically relevant species, while the counter-ion improves handling and dissolution.
The molecular backbone consists of seven amino acid residues joined into a ring through a disulfide bridge. This cyclic conformation is critical for receptor binding. The sequence includes an acetylated N-terminus and an amidated C-terminus, modifications that improve resistance to enzymatic breakdown. One residue is in the D-configuration, a feature that further stabilizes the peptide against protease activity. Together, the ring structure and specific stereochemistry determine selectivity among melanocortin receptor subtypes.
Across literature and commercial listings, the substance appears under several names, including bremelanotide, PT-141, and various brand designations. A CAS registry number provides a unique identifier for the compound, aiding retrieval from chemical databases. Synonym lists may also contain early development codes and descriptive chemical names. When consulting sources, researchers need to confirm that the cited names refer to the same molecular structure to avoid confusion. Naming consistency matters especially when comparing analytical data across publications.
PT-141 is a synthetic cyclic heptapeptide whose development code is bremelanotide. It belongs to the class of melanocortin receptor agonists and acts by mimicking endogenous peptide hormones. The compound originated from research on melanotan II, where investigators exploring derivatives found distinct pharmacological features. Unlike the parent compound, PT-141 showed effects on pathways related to sexual desire and function in early studies, prompting its development as a separate candidate. Its molecular design aimed to separate receptor activity from pigmentary effects.
Handling procedures emphasize minimizing moisture uptake, since the dried solid is hygroscopic and can draw water when warmed to room temperature before a vial is opened. Laboratories record lot number, purity, counter-ion content, and residual solvent data supplied by the producer. Impurity profiles are compared run to run, and any shift in retention time or peak shape prompts re-verification against a reference standard. Certificates of analysis are treated as claims to be checked rather than accepted at face value.
Identity and purity testing for this peptide typically relies on reversed-phase high-performance liquid chromatography with ultraviolet detection, reported as area-percent purity. Mass spectrometry, usually in tandem mode, confirms molecular mass and supports quantification in biological matrices. Sequence confirmation may use peptide mapping after enzymatic digestion, while nuclear magnetic resonance and circular dichroism supply supplementary structural detail. No single technique establishes identity alone, so laboratories compare retention time, mass, and fragment pattern against a verified reference standard.
== Awards and decorations == For his commitment in Asian countries Prof. Rode has received many awards, amongst others the Honorary Doctorate Degree in Sciences of the Chulalongkorn University, Bangkok (1995), the Honorary Doctorate Degree in Sciences of the King Mongkut’s Institute of Technology, Ladkrabang, Bangkok (1998) and the Honorary Doctorate Degree in Sciences of the Gadjah Mada University, Yogyakarta, Indonesia (2000). In 2007 the King of Thailand, awarded Prof. Rode with the Knight Grand Cross (First Class), the Most Noble Order of the Crown of Thailand, for his activities and achievements to intensify the European-Asian scientific collaborations. In 2008 the Comenius University Bratislava awarded him an Honorary Doctorate Degree for his pioneer work in quantum chemistry studies of molecule and super molecule systems of ion solvation and molecular modelling of biomolecules and medicaments. In 2014 he was appointed Honorary President of ASEA-UNINET. Overview most important Awards and Decorations:
In August 2022, the National Labor Relations Board accused the company of illegally discriminating against unionized workers by refusing them wage and benefit increases and requesting restitution. It also asked that the CEO at the time, Howard Schultz, or a board official read a notice about this purportedly unlawful move. That same month, unions were certified at 211 locations in the US. On November 17, 2022, Starbucks’ annual Red Cup Day and one of the busiest days for employees, over 100 locations had employees go on strike. The workers were seeking higher staffing levels, better wages, and consistent schedules. Most unionization efforts are made through SBWU (Starbucks Workers United). There are over 9,000 American locations, but since the first unionized location in New York in 2021, less than 3% have voted to unionize. SBWU and Starbucks have yet to successfully negotiate a contract. Starbucks claims in a letter and on its website that the Workers United has delayed bargaining, has illegally broadcast bargaining sessions, refused to meet in person, and that Starbucks has reported more than 22 unfair labor practice charges to the NLRB (National Labor Relations Board). By March 2023, the NLRB found no merit in Starbucks's complaints and instead ruled that it was Starbucks who refused to bargain. On June 23, 2023, Starbucks workers at unionized stores went on strike over the company's stance on in-store LGBT pride decorations.
The initial list of free agents, published in March 2015, consisted of 74 unrestricted and restricted free agents, however, 35 of those players re-signed and 15 retired during or after the home-and-away season.
=== Eyes === Tacrolimus solution, as drops, is sometimes prescribed by veterinarians for keratoconjunctivitis, and other dry eye maladies, in the eyes of domestic cats, dogs, and horses. It has been studied for use in human eyes.
=== 1988 === February 20: The First Nagorno-Karabakh War was fought between Armenia and Azerbaijan. February 22: USS Yorktown and USS Caron are rammed off the Crimean Peninsula after entering Soviet territorial waters. May 11: Kim Philby (Harold Adrian Russell Philby), the high-ranking UK intelligence officer who defected to the Soviet Union, dies in Moscow. May 15: The Soviets begin withdrawing from Afghanistan. May 29–June 1: Reagan and Gorbachev meet in Moscow. INF Treaty ratified. When asked if he still believes that the Soviet Union is still an evil empire, Reagan replies he was talking about "another time, another era". October 5: Chile's Augusto Pinochet loses a national plebiscite on his rule. November 3: A coup attempt occurred in the Maldives. November 6: Soviet scientist and well-known human rights activist Andrei Sakharov begins a two-week visit to the United States. November 15: The State of Palestine was formally established through the Palestinian Declaration of Independence. December 7: Gorbachev announces in a speech to the United Nations General Assembly that the Soviet Union will no longer militarily interfere with Eastern Europe.
Sources: en.wikipedia.org
Eaton wrote that the "Suburbs were protected from desegregation by the courts, ignoring the origin of their racially segregated housing patterns." John Mogk, an expert in urban planning at Wayne State University in Detroit, has said that "Everybody thinks that it was the riots [in 1967] that caused the white families to leave. Some people were leaving at that time but, really, it was after Milliken that you saw a mass flight to the suburbs. If the case had gone the other way, it is likely that Detroit would not have experienced the steep decline in its tax base that has occurred since then." Myron Orfield, director of the Institute on Metropolitan Opportunity at the University of Minnesota, has said:
===== The movements of the nose are affected by ===== the elevator muscle group – which includes the procerus muscle and the levator labii superioris alaeque nasi muscle. the depressor muscle group – which includes the alar nasalis muscle and the depressor septi nasi muscle. the compressor muscle group – which includes the transverse nasalis muscle. the dilator muscle group – which includes the dilator naris muscle that expands the nostrils; it is in two parts: (i) the dilator nasi anterior muscle, and (ii) the dilator nasi posterior muscle.
In 1987, the company was headquartered in Livonia, Michigan, and Mulder became CEO and president. The freeze was lifted, and a push occurred in 1986, adding 60 franchise units. In March 1989, A&W made an agreement with Minnesota-based Carousel Snack Bars to convert that chain's 200 stores (mostly kiosks in shopping malls) to A&W Hot Dogs & More, Some A&W Hot Dogs & More are still operating. aiming to finish the conversion within two years. In the same year, A&W bought the Burger City chain, converting its nine drive-thru kiosks to A&W units. George E. Michel, who had worked with the Canadian chain for twenty years, was appointed president of the American A&W Restaurants in January 1991, becoming CEO in January 1992. His presidency used its long history as a pretext for nostalgia both in the United States and abroad.
=== Use of social media networks === Almost all Americans who were in their teens and 20s during the late 2010s and early 2020s are on at least one social-media platform. YouTube was the most popular in 2024, followed by TikTok, Instagram, and Snapchat. Meanwhile, Facebook and Twitter have lost grounds among teenagers compared to the 2010s. About three quarters checked their accounts multiple times a day. Members of Generation Z are more likely to "follow" others on social media than "share" and use different types of social media for different purposes. Very few expressed concern about third parties being able to access their data as they share more personal information more often compared to previous generations. Most have uploaded photographs of themselves, stated their interests, given their school names, posted their locations, and revealed their relationship statuses. As a cohort, Generation Z finds validation and social support on social media, where they develop their own individual identities. On the other hand, only a minority engaged in political conversations on social media networks. Despite their heavy usage of social media, a majority believe that life was better before the emergence of these platforms.
== Recognition == In 2018, Icon won PharmaTimes Clinical Researcher of the Year. In 2021, Icon was awarded PharmaTimes Clinical Research Company of the Year, and in 2022, won Best Contract Research Organisation (FSP) at the Scrip Awards. In 2025 Icon was recognized in Forbes World's Top Companies for Women, and in TIME World's Best Companies list. In 2026, the company was recognized by TIME's World's Best Companies in Sustainable Growth for the second consecutive year.
Sources: en.wikipedia.org
PT-141 is a laboratory code for bremelanotide, a synthetic peptide that activates melanocortin receptors. It has been developed both as an injectable pharmaceutical product and as a research chemical. The two contexts differ sharply in how identity, purity, and dosing are controlled.
It is neither a steroid nor a naturally occurring human hormone. Bremelanotide is a manufactured peptide that mimics part of the melanocortin signalling system by binding receptor proteins. Its effects come from receptor activation, not from replacing a circulating hormone.
The internal lactam bridge locks the peptide into a defined shape, which raises receptor affinity and slows enzymatic breakdown. Linear versions of the same sequence are less stable and bind more weakly. Ring geometry is therefore central to how the molecule behaves in the body.
Bremelanotide binds several melanocortin receptors, and MC4R is the subtype most often cited as responsible for its behavioural effects. Activity at MC1R, MC3R and MC5R is also reported. Selectivity is therefore described as limited rather than precise.